Literature DB >> 11369059

Analysis of PTEN/MMAC1 alteration in neuroblastoma.

H Moritake1, Y Horii, H Kuroda, T Sugimoto.   

Abstract

Neuroblastoma is the most common extracranial solid tumor in children. Although it has been reported that loss of heterozygosity at various loci, including 10q, frequently occurs in neuroblastoma, a bona fide tumor suppressor gene has not been identified. Recently, a gene mapped to chromosome 10q23, PTEN/MMAC1, was identified as a tumor suppressor gene that inhibits cell survival and cell proliferation by catalyzing the dephosphorylation of phosphatidylinositol 3,4,5-triphosphate. To screen for mutations of this gene in neuroblastoma, we analyzed 11 primary neuroblastoma tumors and 16 neuroblastoma cell lines for PTEN/MMAC1 mutations and deletions. All nine exons of the PTEN/MMAC1 gene were examined using the polymerase chain reaction-single strand conformational polymorphism assay and sequencing. Only one of the cell lines showed a mutation, a 1-bp frameshift deletion in exon 7, and an allelic loss in the opposite allele was revealed by a microsatellite analysis. Our results indicate that the disruption of the PTEN/MMAC1 gene is not a frequent event in neuroblastoma, and suggest that this disruption may be responsible for malignant progression in only a limited proportion of cases of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369059     DOI: 10.1016/s0165-4608(00)00378-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

1.  Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation.

Authors:  Fumiaki Okahara; Kouichi Itoh; Akira Nakagawara; Makoto Murakami; Yasunori Kanaho; Tomohiko Maehama
Journal:  Mol Biol Cell       Date:  2006-09-13       Impact factor: 4.138

2.  Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

Authors:  Jennifer R Smith; Lucas Moreno; Simon P Heaton; Louis Chesler; Andrew D J Pearson; Michelle D Garrett
Journal:  Mol Oncol       Date:  2015-11-19       Impact factor: 6.603

3.  PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

Authors:  Hal E Crosswell; Anindya Dasgupta; Carlos S Alvarado; Tanya Watt; James G Christensen; Pradip De; Donald L Durden; Harry W Findley
Journal:  BMC Cancer       Date:  2009-11-25       Impact factor: 4.430

4.  Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.

Authors:  Susanne Fransson; Per Kogner; Tommy Martinsson; Katarina Ejeskär
Journal:  J Mol Signal       Date:  2013-04-18

5.  Targeting gastrin-releasing peptide suppresses neuroblastoma progression via upregulation of PTEN signaling.

Authors:  Pritha Paul; Jingbo Qiao; Kwang Woon Kim; Carmelle Romain; Sora Lee; Natasha Volny; Bret Mobley; Hernan Correa; Dai H Chung
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

6.  Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.

Authors:  Anat Erdreich-Epstein; Donald L Durden; Alok R Singh; Shweta Joshi; Francisco M Vega; Pinzheng Guo; Jingying Xu; Susan Groshen; Wei Ye; Melissa Millard; Mihaela Campan; Guillermo Morales; Joseph R Garlich; Peter W Laird; Robert C Seeger; Hiroyuki Shimada
Journal:  Oncotarget       Date:  2016-11-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.